Abstract:Alport syndrome (AS) is a hereditary kidney disease associated with proteinuria, hematuria and progressive kidney failure. It is characterized by a defective glomerular basement membrane caused by mutations in type IV collagen genes COL4A3/A4/A5 which result in defective type IV collagen α3, α4, or α5 chains, respectively. Alport syndrome has three different patterns of inheritance: X-linked, autosomal and digenic. In a study of CKD of unknown etiology type IV collagen gene mutations accounted for the majority of the cases of hereditary glomerulopathies which suggests that AS is often underrecognized. The natural history and prognosis in patients with AS is variable and is determined by genetics and environmental factors. At present, no preventive or curative therapies exist for AS. Current treatment includes the use of renin-angiotensin-aldosterone system inhibitors which slow progression of kidney disease and prolong life expectancy. Ramipril was found in retrospective studies to delay the onset of ESKD and was recently demonstrated to be safe and effective in children and adolescents, supporting that early initiation of Renin Angiotensin Aldosterone System (RAAS) blockade is very important. Mineralocorticoid receptor blockers might be favorable for patients who develop "aldosterone breakthrough." While the DAPA-CKD trial suggests a beneficial effect of SGLT2 inhibitors in CKD of non-metabolic origin, only a handful of patients had Alport in this cohort, and therefore conclusions can't be extrapolated for the treatment of AS with SGLT2 inhibitors. Advances in our understanding on the pathogenesis of Alport syndrome has culminated in the development of innovative therapeutic approaches that are currently under investigation. We will provide a brief overview of novel therapeutic targets to prevent progression of kidney disease in AS. Our review will include bardoxolone methyl, an oral NRf2 activator; lademirsen, an anti-miRNA-21 molecule; sparsentan, dual endothelin type A receptor (ETAR) and angiotensin 1 receptor inhibitor; atrasentan, oral selective ETAR inhibitor; lipid-modifying agents, including cholesterol efflux transporter ATP-binding cassette A1 (ABCA1) inducers, discoidin domain receptor 1 (DDR1) inhibitors and osteopontin blocking agents; the antimalarial drug hydroxychloroquine; the antiglycemic drug metformin and the active vitamin D analog paricalcitol. Future genomic therapeutic strategies such as chaperone therapy, genome editing and stem cell therapy will also be discussed.

Investigation of exon skipping therapy in kidney organoids from Alport syndrome patients derived iPSCs

iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome

Establishment of Microrna, Transcript and Protein Regulatory Networks in Alport Syndrome Induced Pluripotent Stem Cells

Genetic Reprogramming with Stem Cells Regenerates Glomerular Epithelial Podocytes in Alport Syndrome

Pharmacological approach and diagnosis for Alport syndrome

Establishment of the Induced Pluripotent Stem Cell Line (Nckdi005-A) from a Male Patient with Alport Syndrome Carrying a Homozygous Frameshift Mutation in the COL4A4 Gene.

Exploration of Gene Therapy for Alport Syndrome

A Novel COL4A5 Splicing Mutation Causes Skipping of Exon 14 in a Chinese Family with Alport Syndrome

mRNA Analysis Identifies deep Intronic Splicing Variants Leading to Alport Syndrome and Overcomes the Problem of Negative Results of Exome Sequencing

Determination of the Pathogenicity of a Novel COL4A5 Missense Variant by CRISPR-Cas9 in Kidney Podocytes.

mRNA analysis identifies deep intronic variants causing Alport syndrome and overcomes the problem of negative results of exome sequencing

Novel Therapies for Alport Syndrome

Trimerization profile of type IV collagen COL4A5 exon deletion in X-linked Alport syndrome

A mouse model for X-linked Alport syndrome induced by Del-ATGG in the Col4a5 gene

Generation of an Induced Pluripotent Stem Cell Line (Shcdnri001-A) from a Patient with X-linked Alport Syndrome Carrying a Heterozygous P.g409s (c. 1225 G > A) Mutation in the COL4A5 Gene

Synergistic Toxicity of Compound Heterozygous Mutations in the COL4A3 Gene Causes End-Stage Renal Disease in A Large Family of Alport Syndrome

Generation and Characterization of an Integration-Free Ipsc Line SDUBMSi006-A from a Patient with Alport Syndrome Caused by COL4A3 Gene Mutations.

Stem Cell Therapy for Alport Syndrome: the Hope Beyond the Hype

Case report: A novel compound heterozygous variant in the COL4A3 gene was identified in a patient with autosomal recessive Alport syndrome

Functional Assessment of a Novel COL4A5 Splicing Site Variant in a Chinese X-linked Alport Syndrome Family.

NanoLuc reporters identify COL4A5 nonsense mutations susceptible to drug-induced stop codon readthrough